Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: A valve apparatus comprises a valve body defining a flow path therethrough, a valve member mounted within the valve body, and an actuator assembly mounted internally within the valve body. The actuator assembly comprises a piston bore and piston member defining a piston chamber therebetween, wherein at least one of the piston bore and piston member is engaged or associated with the valve member such that the valve member is moveable in accordance with fluid pressure within the piston chamber to selectively occlude the flow path.

Abstract: A valve apparatus comprises a valve body defining a flow path therethrough, a valve member mounted within the valve body, and an actuator assembly mounted internally within the valve body. The actuator assembly comprises a piston bore and piston member defining a piston chamber therebetween, wherein at least one of the piston bore and piston member is engaged or associated with the valve member such that the valve member is moveable in accordance with fluid pressure within the piston chamber to selectively occlude the flow path.

Abstract: A downhole valve, such as a safety valve or sub-sea safety valve (SSSV). The downhole valve comprising: a housing; a flow path between a valve inlet and a valve outlet; a valve mechanism; and a piston member; wherein the valve mechanism is operable by actuation of the piston member to selectively open and close the flow path between the valve inlet and valve outlet; and the piston member is actuatable by a pressure differential between an annulus pressure at the valve and a pressure at the valve outlet and/or in a portion of the flow path closest to the valve outlet. The valve can comprise an opening for receiving the annular pressure that is isolated from the valve inlet and valve outlet. The downhole valve can be configured such that it prevents operation of the valve mechanism to open and/or close the flow path by a pressure differential between the valve inlet and valve outlet.

Abstract: A screen assembly, such as a downhole/sand screen assembly, comprising first and second screen portions or screens longitudinally coupled together, wherein there is provided a fluid flow path between the first and second screen portions or screen. Optionally, the first and second sleeves are coupled or connected by a centraliser or further sleeve or screen, and/or optionally by or via first and second support ring.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: A valve apparatus comprises a valve body defining a flow path therethrough, a valve member mounted within the valve body, and an actuator assembly mounted internally within the valve body. The actuator assembly comprises a piston bore and piston member defining a piston chamber therebetween, wherein at least one of the piston bore and piston member is engaged or associated with the valve member such that the valve member is moveable in accordance with fluid pressure within the piston chamber to selectively occlude the flow path.

Abstract: A downhole valve, such as a safety valve or sub-sea safety valve (SSSV). The downhole valve comprising: a housing; a flow path between a valve inlet and a valve outlet; a valve mechanism; and a piston member; wherein the valve mechanism is operable by actuation of the piston member to selectively open and close the flow path between the valve inlet and valve outlet; and the piston member is actuatable by a pressure differential between an annulus pressure at the valve and a pressure at the valve outlet and/or in a portion of the flow path closest to the valve outlet. The valve can comprise an opening for receiving the annular pressure that is isolated from the valve inlet and valve outlet. The downhole valve can be configured such that it prevents operation of the valve mechanism to open and/or close the flow path by a pressure differential between the valve inlet and valve outlet.

Abstract: A screen assembly, such as a downhole/sand screen assembly, comprising first and second screen portions or screens longitudinally coupled together, wherein there is provided a fluid flow path between the first and second screen portions or screen. Optionally, the first and second sleeves are coupled or connected by a centraliser or further sleeve or screen, and/or optionally by or via first and second support ring.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: A screen assembly, such as a downhole/sand screen assembly, comprising first and second screen portions or screens longitudinally coupled together, wherein there is provided a fluid flow path between the first and second screen portions or screen. Optionally, the first and second sleeves are coupled or connected by a centralizer or further sleeve or screen, and/or optionally by or via first and second support ring.

Abstract: A screen assembly, such as a downhole/sand screen assembly, comprising first and second screen portions or screens longitudinally coupled together, wherein there is provided a fluid flow path between the first and second screen portions or screen. Optionally, the first and second sleeves are coupled or connected by a centralizer or further sleeve or screen, and/or optionally by or via first and second support ring.

Abstract: A method in a clocked integrated circuit receiving an input clock signal having a clock frequency and a command signal for accessing a memory element in the clocked integrated circuit. The method detects the input clock signal having a clock frequency above or below a frequency threshold. The method generates a clock detect output signal having a first logical state in response to the clock frequency being below the frequency threshold and generates the clock detect output signal having a second logical state in response to the clock frequency being above the frequency threshold. The method delays the command signal by a first timing latency to generate a timing adjusted control signal where the first timing latency is one or more clock periods of the input clock signal. Finally, the method adjusts the first timing latency in response to the clock detect output signal.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.

Abstract: Disclosed are methods for treating a patient suffering from osteogenesis imperfecta comprising administering to the patient a therapeutically effective amount of an anti-sclerostin antibody. Methods for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient by administering to the patient a therapeutically effective amount of an anti-sclerostin antibody are also disclosed. Further disclosed are compositions for increasing bone formation and reducing bone resorption in an osteogenesis imperfecta patient. The compositions comprise a therapeutically effective amount of an anti-sclerostin antibody. The invention also provides an anti-sclerostin antibody for use in the treatment of osteogenesis imperfecta.